Can mHealth Technology Help Mitigate the Effects of the COVID-19 Pandemic?

Catherine Adans-Dester, Stacy Bamberg, Francesco Bertacchi, Brian Caulfield, Kara Chappie, Danilo Demarchi, Michael Kelley Erb, Juan Estrada, Eric Fabara, Michael Freni, Karl E. Friedl, Roozbeh Ghaffari, Geoffrey Gill, Mark S. Greenberg, Reed W. Hoyt, Emil Jovanov, Christoph M. Kanzler, Dina Katabi, Meredith Kernan, Colleen M Kigin, Sunghoon Ivan Lee, Steffen Leonhardt, Nigel H. Lovell, Jose Mantilla, Thomas H. McCoy, Nell Meosky Luo, Glenn A. Miller, John T. Moore, Derek T. O’Keeffe, Jeffrey S. Palmer, Federico Parisi, Shyamal Patel, Jack Po, Benito L. Pugliese, Thomas F. Quatieri, Tauhidur Rahman, Nathan Ramasarma, John A. Rogers, Guillermo U. Ruiz‐Esparza, Stefano Sapienza, Gregory Schiurring, Lee H. Schwamm, Hadi Shafiee, Sara Silacci, Nathaniel M. Sims, Tanya Talkar, William J. Tharion, James A. Toombs, Christopher Uschnig, Gloria Vergara-Díaz, Paul W. Wacnik, May D. Wang, James Welch, Lina Williamson, Ross Zafonte, Adrian Zai, Yuan‐Ting Zhang, Guillermo J. Tearney, Rushdy Ahmad, David R. Walt, Paolo BonatoIEEE Open Journal of Engineering in Medicine and Biology 2020 · DOI

Abstract

Goal: The aim of the study herein reported was to review mobile health (mHealth) technologies and explore their use to monitor and mitigate the effects of the COVID-19 pandemic. Methods: A Task Force was assembled by recruiting individuals with expertise in electronic Patient-Reported Outcomes (ePRO), wearable sensors, and digital contact tracing technologies. Its members collected and discussed available information and summarized it in a series of reports. Results: The Task Force identified technologies that could be deployed in response to the COVID-19 pandemic and would likely be suitable for future pandemics. Criteria for their evaluation were agreed upon and applied to these systems. Conclusions: mHealth technologies are viable options to monitor COVID-19 patients and be used to predict symptom escalation for earlier intervention. These technologies could also be utilized to monitor individuals who are presumed non-infected and enable prediction of exposure to SARS-CoV-2, thus facilitating the prioritization of diagnostic testing.

Introduction

The COVID-19 pandemic presented an unprecedented challenge to global healthcare systems, characterized by a high volume of patients with symptoms ranging from asymptomatic to fatal. The rapid progression of the disease and its "silent" spread by pre-symptomatic individuals made containment exceptionally difficult. This paper, produced by a multidisciplinary Task Force from the Mass General Brigham (MGB) Center for COVID Innovation, evaluates how mobile health (mHealth) technologies can bridge the gap between clinical capacity and population-scale monitoring.

The authors propose a framework where remote data collection—specifically electronic patient-reported outcomes (ePRO), wearable sensors, and digital contact tracing—feeds into probabilistic models. This approach aims to prioritize diagnostic testing and predict clinical worsening before it becomes critical.

Methodology and Technology Categorization

The Task Force categorized mHealth tools into three functional domains to address different aspects of the pandemic:

  1. Electronic Patient-Reported Outcomes (ePRO): Digital surveys that allow individuals to self-report signs and symptoms, providing a subjective but scalable data stream.
  2. Wearable Sensors: Consumer-grade and medical-grade devices that track physiological data such as resting heart rate, respiratory rate, and oxygen saturation ($SpO_2$).
  3. Digital Contact Tracing: Smartphone applications utilizing Bluetooth technology to log proximity to individuals who have tested positive for the virus.
Integration of wearable devices like smartwatches with mobile applications allows for continuous physiological monitoring.

The methodology involved synthesizing findings from clinical reports (e.g., data from South Korea and NYU Langone) and historical mHealth studies to create a schematic for a "probabilistic model" that aggregates these data streams to estimate infection likelihood.

Key Insights: The "Silent" Predictor

A central insight of the study is the role of wearable sensors in detecting physiological "abnormalities" before they are consciously felt by the patient. For instance, a slight drop in $SpO_2$ or a rise in resting heart rate can serve as an early warning sign of viral infection or clinical exacerbation.

Smart rings and associated apps can detect subtle physiological changes, such as heart rate variability, which may indicate early-stage infection.

Furthermore, the authors emphasize that mHealth is not just for the symptomatic. It serves as a tool for the "presumed non-infected" to enable early detection and for "survivors" to monitor long-term post-COVID conditions (sequelae).

Results and Strategic Framework

The paper concludes that mHealth is a viable, scalable solution for pandemic management. Key findings include:

  • Clinical Utility of $SpO_2$: Monitoring oxygen saturation is identified as the most critical metric for predicting sudden worsening in home-quarantined patients.
  • Prioritization of Testing: By using mHealth data to identify individuals with a "high to moderate probability" of infection, healthcare providers can more efficiently allocate scarce PCR testing resources.
  • Adoption Thresholds: For digital contact tracing to be effective in suppressing an epidemic, the authors highlight that approximately 80% of smartphone users in a population must adopt the technology.

Challenges and Future Directions

Despite the potential, several hurdles remain:

  • False Positives: High-density environments may trigger an unmanageable number of contact tracing alerts that do not result in actual transmission.
  • Adoption and Equity: Cultural, economic, and privacy concerns are significant barriers, particularly in underrepresented communities.
  • Data Integration: Integrating mHealth data into Electronic Health Records (EHR) remains a technical and bureaucratic challenge.

Future work should focus on "pooling" samples for testing based on mHealth risk scores and integrating immune status (antibody) data into the probabilistic models to refine risk assessments.

Summary updated

Abstract

<i>Goal:</i> The aim of the study herein reported was to review mobile health (mHealth) technologies and explore their use to monitor and mitigate the effects of the COVID-19 pandemic. <i>Methods:</i> A Task Force was assembled by recruiting individuals with expertise in electronic Patient-Reported Outcomes (ePRO), wearable sensors, and digital contact tracing technologies. Its members collected and discussed available information and summarized it in a series of reports. <i>Results:</i> The Task Force identified technologies that could be deployed in response to the COVID-19 pandemic and would likely be suitable for future pandemics. Criteria for their evaluation were agreed upon and applied to these systems. <i>Conclusions:</i> mHealth technologies are viable options to monitor COVID-19 patients and be used to predict symptom escalation for earlier intervention. These technologies could also be utilized to monitor individuals who are presumed non-infected and enable prediction of exposure to SARS-CoV-2, thus facilitating the prioritization of diagnostic testing.
BibTeX
@article{adansdester2020can,
  author = {Catherine Adans-Dester and Stacy Bamberg and Francesco Bertacchi and Brian Caulfield and Kara Chappie and Danilo Demarchi and Michael Kelley Erb and Juan Estrada and Eric Fabara and Michael Freni and Karl E. Friedl and Roozbeh Ghaffari and Geoffrey Gill and Mark S. Greenberg and Reed W. Hoyt and Emil Jovanov and Christoph M. Kanzler and Dina Katabi and Meredith Kernan and Colleen M Kigin and Sunghoon Ivan Lee and Steffen Leonhardt and Nigel H. Lovell and Jose Mantilla and Thomas H. McCoy and Nell Meosky Luo and Glenn A. Miller and John T. Moore and Derek T. O’Keeffe and Jeffrey S. Palmer and Federico Parisi and Shyamal Patel and Jack Po and Benito L. Pugliese and Thomas F. Quatieri and Tauhidur Rahman and Nathan Ramasarma and John A. Rogers and Guillermo U. Ruiz‐Esparza and Stefano Sapienza and Gregory Schiurring and Lee H. Schwamm and Hadi Shafiee and Sara Silacci and Nathaniel M. Sims and Tanya Talkar and William J. Tharion and James A. Toombs and Christopher Uschnig and Gloria Vergara-Díaz and Paul W. Wacnik and May D. Wang and James Welch and Lina Williamson and Ross Zafonte and Adrian Zai and Yuan‐Ting Zhang and Guillermo J. Tearney and Rushdy Ahmad and David R. Walt and Paolo Bonato},
  title = {{Can mHealth Technology Help Mitigate the Effects of the COVID-19 Pandemic?}},
  journal = {IEEE Open Journal of Engineering in Medicine and Biology},
  year = {2020},
  doi = {10.1109/ojemb.2020.3015141},
}
Figure